Pfizer Inc. (NYSE:PFE) was the target of a large growth in short interest in the month of October. As of October 30th, there was short interest totalling 45,930,000 shares, a growth of 13.6% from the October 15th total of 40,440,000 shares. Based on an average daily volume of 26,830,000 shares, the days-to-cover ratio is currently 1.7 days.
NYSE:PFE traded up $0.51 during mid-day trading on Friday, hitting $36.70. The stock had a trading volume of 60,633,847 shares, compared to its average volume of 30,295,137. The company has a current ratio of 1.42, a quick ratio of 1.16 and a debt-to-equity ratio of 0.78. The company has a 50 day simple moving average of $37.02 and a 200-day simple moving average of $36.60. The stock has a market capitalization of $203.99 billion, a price-to-earnings ratio of 14.56, a P/E/G ratio of 3.10 and a beta of 0.66. Pfizer has a 52 week low of $27.88 and a 52 week high of $41.99.
Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, October 27th. The biopharmaceutical company reported $0.72 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.71 by $0.01. The company had revenue of $12.13 billion for the quarter, compared to analysts’ expectations of $12.30 billion. Pfizer had a return on equity of 25.11% and a net margin of 28.80%. The business’s revenue for the quarter was down 4.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.75 earnings per share. As a group, equities research analysts anticipate that Pfizer will post 2.84 earnings per share for the current year.
In other news, major shareholder Pfizer Inc acquired 1,200,000 shares of the business’s stock in a transaction on Tuesday, October 27th. The stock was bought at an average price of $10.00 per share, with a total value of $12,000,000.00. Following the completion of the acquisition, the insider now owns 27,349,211 shares of the company’s stock, valued at $273,492,110. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.08% of the stock is owned by company insiders.
Several institutional investors and hedge funds have recently modified their holdings of the company. Assenagon Asset Management S.A. bought a new stake in shares of Pfizer during the 2nd quarter worth about $233,000. Creative Financial Designs Inc. ADV lifted its position in Pfizer by 60.3% in the second quarter. Creative Financial Designs Inc. ADV now owns 2,773 shares of the biopharmaceutical company’s stock worth $91,000 after purchasing an additional 1,043 shares during the period. Congress Asset Management Co. MA boosted its stake in Pfizer by 4.4% during the 2nd quarter. Congress Asset Management Co. MA now owns 9,547 shares of the biopharmaceutical company’s stock valued at $312,000 after purchasing an additional 400 shares in the last quarter. Atwater Malick LLC boosted its stake in Pfizer by 3.5% during the 2nd quarter. Atwater Malick LLC now owns 122,150 shares of the biopharmaceutical company’s stock valued at $3,994,000 after purchasing an additional 4,166 shares in the last quarter. Finally, BTR Capital Management Inc. increased its position in shares of Pfizer by 0.7% during the 2nd quarter. BTR Capital Management Inc. now owns 262,155 shares of the biopharmaceutical company’s stock valued at $8,572,000 after purchasing an additional 1,859 shares during the period. 69.08% of the stock is currently owned by institutional investors.
A number of brokerages have commented on PFE. Morgan Stanley lifted their target price on shares of Pfizer from $36.00 to $42.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 30th. Sanford C. Bernstein assumed coverage on shares of Pfizer in a research note on Tuesday, November 10th. They set a “market perform” rating and a $42.00 price target on the stock. UBS Group increased their price objective on Pfizer from $37.00 to $39.00 and gave the company a “neutral” rating in a research note on Wednesday, July 29th. Zacks Investment Research upgraded shares of Pfizer from a “sell” rating to a “hold” rating and set a $37.00 price target for the company in a research note on Thursday, October 29th. Finally, JPMorgan Chase & Co. set a $36.00 price objective on Pfizer and gave the stock a “neutral” rating in a research report on Monday, November 9th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating and five have issued a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $39.80.
Pfizer Inc develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Sutent, Xtandi, Xalkori, Inlyta, Braftovi + Mektovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Vfend, and Zithromax brands.
Featured Story: Benefits of owning preferred stock
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.